" class="no-js "lang="en-US"> Dr. Jacqueline Sneddon, BSAC, on Antibiotics
Friday, June 09, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases

May 12 2023

Dr. Jacqueline Sneddon, BSAC, on Antibiotics

At the 33rd ECCMID event, we caught up with Dr. Jacqueline Sneddon, the Programmes Manager of the British Society for Antimicrobial Chemotherapy (BSAC), as she discusses the important issue of antibiotics and antimicrobial stewardship. She highlights the increasing problem of antimicrobial resistance and the need for effective stewardship to ensure the continued effectiveness of antibiotics.

Sneddon emphasizes the importance of educating healthcare professionals and the general public about the appropriate use of antibiotics and the problem of antimicrobial resistance. She highlights the role of organizations like BSAC in promoting awareness and providing education and resources to support stewardship efforts.

  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

    Gene Therapy

     Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

    Diseases

     Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas

    Clinical Trials

     Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

    News

     Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

    Drug Development

     Read more
More On